Scientific Evidence
Peer-reviewed evidence base on biofeedback and neurofeedback, focusing on systematic reviews and meta-analyses (2010-2026).
From summary to detail: overview, condition cards, then equipment certification.
This page focuses on aggregate numbers and condition cards; for physiology mechanisms and long-form articles, use Research and, for clinical context by topic, the therapy hub. CE and ISO certification for devices is in the dedicated section below.
The platform is grounded in peer-reviewed literature. The matrix below summarizes evidence levels; it does not replace medical advice.
Studies and certification connect to certified training paths and professional devices on the same platform.
The platform is grounded in scientific evidence. Filipa and the team maintain and update this evidence base.
Biofeedback as a therapeutic modality has been the subject of clinical research since the 1960s. The evidence base now encompasses thousands of published studies. We focus on systematic reviews, meta-analyses, and high-quality randomized controlled trials.
Findings from systematic reviews and meta-analyses published in indexed peer-reviewed journals.
Biofeedback significantly reduced headache frequency and severity vs. waitlist control. No significant difference vs. pharmacotherapy or CBT, establishing clinical equivalence. Synergistic benefit when combined with medication.
Mishra et al. ScienceDirect, 2025 (SR/MA, 558 participants). Nestoriuc et al. Appl Psychophysiol Biofeedback, 2008.
Consistent efficacy as complementary therapy across diverse chronic pain conditions, with significant reductions in pain intensity and quality of life improvements. EMG biofeedback particularly effective for musculoskeletal pain; HRV biofeedback for central sensitization syndromes.
Constans et al. ScienceDirect/PMC, 2025 (PRISMA SR, 2014-2024). Lazaridou et al. 2023 (RCT, chronic low back pain).
Significant positive effects on: hypertension and cardiovascular prognosis, inflammatory state, asthma management, depression and anxiety, sleep disturbances, and cognitive performance. No adverse effects reported.
Lalanza et al. Appl Psychophysiol Biofeedback, 2023 (PRISMA SR, 143 studies). SR Diabetes & Metabolic Syndrome, 2024 (29 articles).
Statistically superior to waitlist control. Multi-modal biofeedback (combined HRV + GSR + EEG) was most effective, suggesting broader physiological coverage increases therapeutic efficacy. Anxiety was the most commonly treated condition (68.3% of studies). A 4-week RCT (n=52) showed significant improvements in anxiety, depression, and insomnia (p<0.05).
Tolin et al. Adv Exp Med Biol 2020 (SR). Wang et al. Appl Psychophysiol Biofeedback 49(1):71–83, 2024 (RCT, n=52). Guidi et al. PubMed PMID: 33792548.
Large effect sizes in MDD studies: Hedges' g = 1.050 (between-group). HRV biofeedback: meta-analyses report g=0.38–0.48; 34% superior to treatment as usual; remote HRVB effective (18 studies, N=1,352). Neurofeedback outperformed rTMS and tDCS in enhancing cognitive function. Dose-response relationship confirmed.
Pizzoli et al. Scientific Reports 2021 (14 RCTs, g=0.38). Donnelly et al. Acta Biomedica 2023 (9 RCTs, g=0.478). Springer Appl Psychophysiol Biofeedback 2025 (18 studies, remote HRVB). Fernandez-Alvarez et al. Psychological Medicine 2022.
Neurofeedback vs. passive controls: moderate-to-large effect (SMD = 0.64; p = 0.002). Neurophysiological changes (alpha rhythm normalization) correlated with clinical improvement. Meaningful adjunct given 39-72% non-response to standard psychotherapy in military populations.
Voigt et al. Frontiers in Psychiatry, 2024 (SR/MA, 17 RCTs, 628 patients). Askovic et al. Eur J Psychotraumatology, 2023.
Clear, consistent evidence of benefit as adjunctive therapy for urinary incontinence following prostatectomy and fecal incontinence. Medicare-reimbursable in the U.S. (NCD 30.1).
Kondo et al. VA Evidence Synthesis Program, 2019 (Evidence Map, 16 systematic reviews). PMC6854143.
Neurofeedback improves reaction time, cognitive performance, and emotional regulation across diverse sports (archery, soccer, volleyball, judo). Biofeedback aligns with stress resilience; neurofeedback with cognitive-motor optimization. Optimal protocol: 4-10 weeks, 2-3 sessions/week.
Tosti et al. Brain Sciences, 2024 (PRISMA SR, 24 studies). Frontiers in Psychology, 2025 (Bayesian MA).
HRV biofeedback in breast cancer survivors: significant increase in low-frequency HRV (p = 0.027), long-lasting sleep quality improvement, and psychological well-being maintained at 6-month follow-up.
Three-arm longitudinal RCT, 60 post-treatment breast cancer patients, UK, 2025.
Cognitive (MoCA), motor (Fugl-Meyer), psychological (perceived stress), and autonomic function all improved at 3 and 6 months. Benefits became more pronounced over time.
RCT, 62 ischemic stroke patients. ScienceDirect, 2024.
89% of included studies reported positive outcomes for occupational stress reduction. Breathing-based biofeedback targeting HRV was particularly effective. Mobile app-directed and short-session interventions showed particular promise for resilience building.
PubMed, 2025. PMID: 40939175 (PRISMA, 2012-2024).
EEG neurofeedback combined with standard pharmacotherapy significantly improved both positive and negative symptoms of schizophrenia compared to medication alone.
Duan et al. Frontiers in Psychiatry, 2025 (SR/MA, 14 studies, 1,371 participants).
EEG-based neurofeedback shows efficacy as an adjunct for binge-eating disorder in systematic reviews and meta-analyses of RCTs. Pilot RCTs of EEG neurofeedback in adults with binge eating and overweight reduced objective binge episodes and eating-disorder psychopathology; some participants maintained abstinence at follow-up. Digital interventions including biofeedback in obesity management show modest effects (e.g. waist circumference). Position as complement to multidisciplinary approaches, not as replacement.
SR/MA neurofeedback for binge eating, ScienceDirect. Neurotherapeutics 2021 (pilot RCT, N=39; PMC9130382). Nutrients 2025, SR/MA of e-health/m-health interventions in obesity (PubMed 40647304).
Short PRISMA systematic reviews and studies of biofeedback and neurofeedback in smokers suggest that training may modulate craving and smoking-related brain plasticity. The Cochrane review on feedback about the effects of smoking on the body found no clear evidence that such feedback increases cessation rates. The literature supports the use of biofeedback as complementary support during the cessation process, not as a guarantee of quitting.
The effect of biofeedback on smoking cessation–a systematic short review, PMC8825623 (2021). Advances in biofeedback and neurofeedback studies on smoking, ScienceDirect 2020. Frontiers in Behavioral Neuroscience 2023 (biofeedback+neurofeedback and cessation status). Cochrane CD004705.
HRV biofeedback in a pilot (n=28) showed medium-large effect on fatigue and superior cognitive outcomes vs. graded exercise. Position as complement to multidisciplinary approaches.
Vos-Vromans et al. J Psychosomatic Research 2016. doi:10.1016/j.jpsychores.2016.12.001
A randomized trial of biofeedback-assisted relaxation in mild asthma patients (N=16) showed reduced asthma severity, lower bronchodilator use, improved pulmonary function, and immune markers (reduced neutrophils and basophils). Evidence for allergic desensitization per se (e.g. IgE-mediated) comes from immunotherapy, not biofeedback. Biofeedback may be considered as complementary support in the management of allergic reactivity and stress-mediated components, not as a replacement for established treatment.
Asthma Severity, Psychophysiological Indicators of Arousal, and Immune Function in Asthma Patients Undergoing Biofeedback-Assisted Relaxation, Appl Psychophysiol Biofeedback 2000 (Springer).
Consolidated evidence levels across all conditions reviewed.
| Condition | Evidence Level | Key Finding |
|---|---|---|
| Headache / Migraine | Strong | Equivalent to pharmacotherapy; synergistic when combined |
| Chronic Pain (multi-condition) | Strong | Pain + QoL improvements across diverse conditions |
| HRV / Cardiovascular | Strong | Multi-system benefits; established protocol guidelines |
| Post-Prostatectomy Incontinence | Strong | Consistent benefit; Medicare-reimbursable (USA) |
| Anxiety Disorders | Moderate-Strong | Superior to waitlist; multi-modal most effective |
| Depression (MDD) | Moderate-Strong | Hedges' g = 0.60-1.05; NF > rTMS for cognition |
| PTSD / Trauma | Moderate | SMD = 0.64 vs. passive control; 17 RCTs, 628 patients |
| Sports Performance | Moderate | Reaction time, cognition, emotional regulation across sports |
| Cancer Survivorship | Moderate | HRV-BFB improves sleep, HRV, well-being post-treatment |
| Post-Stroke Rehabilitation | Moderate | Cognitive + motor + autonomic improvements at 6 months |
| Occupational Stress | Moderate | 89% positive outcomes; HRV breathing most effective |
| Schizophrenia (+ medication) | Moderate | EEG-NF + medication > medication alone for +/- symptoms |
| Fibromyalgia (EEG-NF) | Preliminary | SMR-NF most promising; EMG-BFB less effective |
| SCIO-specific (fibromyalgia) | Preliminary | Favorable clinical results; double-blind trial registered |
| Weight management / Binge eating | Moderate | NF as adjunct for binge eating (SR/MA, RCT); digital interventions modest in obesity |
| Chronic Fatigue Syndrome | Moderate | HRVB: medium-large effect on fatigue; superior cognitive outcomes (Vos-Vromans et al. 2016) |
| Support during smoking cessation | Preliminary | Biofeedback/NF and craving; Cochrane inconclusive for feedback; use as complement |
| Allergy / Allergic reactivity | Preliminary | Biofeedback-assisted relaxation in asthma (RCT N=16); complementary support, not desensitization |
Selected studies from the evidence base, with DOI links.
| Study | Condition | Key Finding | DOI |
|---|---|---|---|
| Wang et al. 2024 (RCT, n=52) | Anxiety, Depression, Insomnia | Significant improvements on all measures (p<0.05) after 4 weeks | 10.1007/s10484-023-09612-3 |
| Pizzoli et al. 2021 (14 RCTs, N=794) | Depression | HRVB: g=0.38, p=0.0006 | 10.1038/s41598-021-86149-7 |
| Donnelly et al. 2023 (9 RCTs, N=428) | Depression | HRVB: g=0.478; 34% better than TAU | 10.23750/abm.v94i4.14305 |
| Springer 2025 (18 studies, N=1,352) | Depression | Remote HRVB: g=-0.41; HRV +g=0.443 | 10.1007/s10484-025-09750-w |
| Tolin et al. 2020 (Systematic Review) | Anxiety (DSM) | Superior to waitlist across all DSM anxiety disorders | 10.1007/978-981-32-9705-0_16 |
| Fournié et al. 2021 (29 studies SR) | Multiple chronic conditions | Positive effects across 8 conditions; no adverse effects | 10.1016/j.ctim.2021.102750 |
| Tosti et al. 2024 Frontiers | ADHD, Anxiety, ASD, Smoking | Effective across multiple conditions; improved ANS function | 10.3389/fnins.2024.1358481 |
| Vos-Vromans et al. 2016 (Pilot, n=28) | Chronic Fatigue Syndrome | Medium-large effect on fatigue; superior cognitive outcomes | 10.1016/j.jpsychores.2016.12.001 |
| Heinz et al. 2025 NEJM AI (RCT, n=210) | GAD + MDD (chatbot) | GenAI chatbot: GAD d=0.79–0.84; alliance comparable to human | 10.1056/AIoa2400802 |
| Habicht et al. 2024 (RCT, n=540) | Anxiety + Depression (chatbot) | 3× engagement; 2.4× usage vs. static CBT | 10.1101/2024.11.01.24316565 |
All sources cited are peer-reviewed publications from indexed journals. You can search the database directly.
Mandelay Q9 and SCIO carry the CE Mark and meet international standards. Certification documentation can be requested via our contact details or viewed on the manufacturer's website.
Conformity with European health, safety and environmental standards.
Mandelay Q9: ISO 13485:2016. Equipment verifiable with the manufacturer.
We recommend confirming with your therapist that the equipment used has valid certification and manufacturer documentation.
Certified equipment and scientific evidence. Discover our services and training.
